Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance

Summary

The pattern of clearance of intravenously administered heparin suggests the participation of a saturable mechanism which has been ascribed to heparin binding to the endothelium. Another potential site of heparin binding which may contribute to the saturable mechanism is the red blood cells. We have examined this possibility using unfractionated heparin together with a chemically-modified low affinity heparin labelled with tritium as tracer. Unfractionated heparin and the radioactive tracer were added to pooled plasma at a fixed concentration. The heparinized plasma was mixed with red cells to reconstitute whole blood. After centrifugation, the radioactivity, APTT, anti-Xa and anti-Ila activities were measured in the resultant plasmas. No evidence of significant binding to red cells could be detected even when the hematocrits of the reconstituted whole blood were increased. These results are at variance with those of a previously published report. We conclude that red cell binding does not contribute to the saturable mechanism of heparin clearance.

• References

• 1 De Swart CA M, Nijmeyer B, Roelofs JM M, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258
• 2 Boneu B, Caranobe C, Gabaig AM, Dupouy D, Sie P, Buchanan MR, Hirsh J. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res 1987; 46: 835-844
• 3 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 4 van Rijn JL M L, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-222
• 5 Barzu T, van Rijn JL M L, Petitou M, Tobelem G, Caen JP. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601-609
• 6 Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Haemos-tas 1988; 14: 18-27
• 7 Caranobe C, Barret A, Gabaig AM, Dupouy D, Sie P, Boneu B. Dissappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res 1985; 40: 129-133
• 8 Melissari E, Thye C, Scully MF, Kakkar VV. Influence of whole blood on standard curve for heparin measurement - possible heparin binding by red cells. Thromb Haemostas 1989; 61: 262-265
• 9 Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, Porta R, Prino G, Torn G, Zoppetti G. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneim-Forsch/Drug Res 1986; 36: 637-642
• 10 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 11 Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA. Thromb Res 1978; 13: 285-286
• 12 Young E. The monitoring of low molecular weight (LMW) heparins in the clinical chemistry laboratory. Abstracts of the 4th Asian-Pacific Congress of Clinical Biochemistry, August 1988: 160
• 13 Hatton MW C, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in mammalian aorta. Thromb Res 1978; 13: 655-670
• 14 Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-334
• 15 Tollefsen DM. Heparin cofactor II. In: Heparin, Chemical and Biological Properties, Clinical Applications. Lane DA, Lindahl U. (eds). CRC Press Inc; Boca Raton: 1989: 257-273
• 16 Pescador R, Porta R, Niada R, Diamantini G, Fedeli G, Mantovani M. The anticoagulant, hepatic lipase-releasing and lipoprotein lipase-releasing activities of several natural and chemically modified heparins differ. Biochem Pharmacol 1987; 36: 253-257
• 17 Cortelazzo S, Buchanan MR, Young E, Hirsh J, Anvari N, Van Ryn-McKenna J, Ofosu FA. Continuous infusion of low affinity heparin and dermatan sulphate induce the release into rabbit blood of a moiety which catalyzes thrombin-antithrombin III formation. Thromb Hem Dis (in press).
• 18 Jackson DM, Nutt ME. Intercellular plasma and its effect on absolute ,red cell volume determination. J Physiol (Lond) 1951; 115: 196-205
• 19 Fairbanks VF. Nonequivalence of automated and manual hematocrit and erythrocytic indices. Am J Clin Pathol 1980; 73: 55-62
• 20 Oosta GM, Favreau LV, Beeler DL, Rosenberg RD. Purification and properties of human platelet heparitinase. J Biol Chem 1982; 257: 11249-11255
• 21 Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, Vlodavsky I. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. J Clin Invest 1985; 76: 1306-1313
• 22 Marciniak E. Binding of heparin in vitro and in vivo to plasma proteins. J Lab Clin Med 1974; 84: 344-356
• 23 Lyon SG, Lasser EC, Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb Haemostas 1987; 58: 884-887
• 24 Leung L, Saigo K, Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood 1989; 73: 177-184